Driehaus Capital Management LLC Has $29.15 Million Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)

Driehaus Capital Management LLC lifted its holdings in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) by 61.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,581,760 shares of the company's stock after acquiring an additional 600,438 shares during the period. Driehaus Capital Management LLC owned approximately 4.73% of MBX Biosciences worth $29,152,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MBX. BNP Paribas Financial Markets acquired a new stake in shares of MBX Biosciences during the 4th quarter worth about $27,000. Virtus ETF Advisers LLC bought a new stake in shares of MBX Biosciences in the 4th quarter worth $64,000. The Manufacturers Life Insurance Company boosted its holdings in MBX Biosciences by 7.5% during the fourth quarter. The Manufacturers Life Insurance Company now owns 49,675 shares of the company's stock worth $916,000 after buying an additional 3,481 shares in the last quarter. Corebridge Financial Inc. acquired a new stake in shares of MBX Biosciences during the fourth quarter worth $103,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of MBX Biosciences during the fourth quarter valued at approximately $108,000.

MBX Biosciences Trading Down 0.9%

Shares of MBX Biosciences stock traded down $0.09 during trading hours on Wednesday, reaching $10.18. The stock had a trading volume of 89,942 shares, compared to its average volume of 250,347. The stock's 50 day moving average is $8.50 and its 200 day moving average is $13.40. MBX Biosciences, Inc. has a twelve month low of $4.81 and a twelve month high of $27.50.

Analyst Ratings Changes

A number of equities research analysts have issued reports on MBX shares. Citizens Jmp began coverage on shares of MBX Biosciences in a report on Thursday, April 10th. They set an "outperform" rating and a $38.00 price target for the company. JMP Securities began coverage on MBX Biosciences in a report on Thursday, April 10th. They issued a "market outperform" rating and a $38.00 price objective for the company. Finally, Guggenheim reaffirmed a "buy" rating and set a $44.00 price target on shares of MBX Biosciences in a research report on Thursday, April 10th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $37.50.

Insider Transactions at MBX Biosciences

In related news, Director Carl L. Gordon bought 47,502 shares of the company's stock in a transaction on Friday, February 14th. The stock was bought at an average cost of $9.87 per share, with a total value of $468,844.74. Following the completion of the acquisition, the director now owns 3,205,930 shares in the company, valued at approximately $31,642,529.10. This represents a 1.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ora H. Pescovitz acquired 7,693 shares of the business's stock in a transaction dated Tuesday, April 8th. The shares were bought at an average price of $5.89 per share, for a total transaction of $45,311.77. Following the completion of the acquisition, the director now owns 24,329 shares in the company, valued at approximately $143,297.81. This trade represents a 46.24% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 198,365 shares of company stock valued at $2,066,119. Corporate insiders own 52.19% of the company's stock.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.